Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Fulcrum Therapeutics, Inc. (FULC : NSDQ)
 
 • Company Description   
Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.

Number of Employees: 104

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.30 Daily Weekly Monthly
20 Day Moving Average: 834,872 shares
Shares Outstanding: 40.85 (millions)
Market Capitalization: $339.04 (millions)
Beta: 2.52
52 Week High: $33.10
52 Week Low: $6.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -37.41% -31.41%
12 Week -18.71% -11.79%
Year To Date -53.08% -44.21%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
26 LANDSDOWNE STREET
-
CAMBRIDGE,MA 02139
USA
ph: 617-651-8851
fax: -
cwaarich@fulcrumtx.com http://www.fulcrumtx.com
 
 • General Corporate Information   
Officers
Bryan Stuart - Chief Executive Officer and President
Kate Haviland - Chairman
Esther Rajavelu - Chief Financial Officer
Peter Thomson - Vice President; Finance and Accounting
Sonja Banks - Director

Peer Information
Fulcrum Therapeutics, Inc. (CORR.)
Fulcrum Therapeutics, Inc. (RSPI)
Fulcrum Therapeutics, Inc. (CGXP)
Fulcrum Therapeutics, Inc. (BGEN)
Fulcrum Therapeutics, Inc. (GTBP)
Fulcrum Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 359616109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 40.85
Most Recent Split Date: (:1)
Beta: 2.52
Market Capitalization: $339.04 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.61 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 12.20% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.78
Price/Cash Flow: -
Price / Sales: 19.98
EPS Growth
vs. Year Ago Period: -18.52%
vs. Previous Quarter: -10.34%
Sales Growth
vs. Year Ago Period: -45.88%
vs. Previous Quarter: -48.75%
ROE
03/31/22 - -48.38
12/31/21 - -47.50
09/30/21 - -53.21
ROA
03/31/22 - -42.31
12/31/21 - -41.20
09/30/21 - -44.20
Current Ratio
03/31/22 - 10.94
12/31/21 - 11.77
09/30/21 - 11.95
Quick Ratio
03/31/22 - 10.94
12/31/21 - 11.77
09/30/21 - 11.95
Operating Margin
03/31/22 - -529.15
12/31/21 - -421.89
09/30/21 - -409.62
Net Margin
03/31/22 - -529.15
12/31/21 - -421.89
09/30/21 - -409.62
Pre-Tax Margin
03/31/22 - -529.15
12/31/21 - -421.89
09/30/21 - -409.62
Book Value
03/31/22 - 4.63
12/31/21 - 5.22
09/30/21 - 5.69
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©